Inflammatory toxicities resulting from CAR T-cell therapy are common, but clinical features contributing to risk of these toxicities are not well understood. Saini et al. profiled peripheral blood cells of B-cell lymphoma patients prior to CD19-targeting CAR T-cell treatment and found that patients with clonal hematopoiesis (CH) were more likely to experience severe toxicities and therapy-related myeloid neoplasms compared to patients without CH. CH driven by mutations in DNMT3A, TET2, or ASXL1 conferred an especially greater risk of toxicity. This study highlights a high-risk segment of the CAR T recipient patient population and adds to the body of work associating CH with various inflammatory conditions.

See article, p. 385.

Relapse of acute myeloid leukemia (AML) after allogeneic bone marrow transplantation has been linked to immune evasion due to reduced expression of major histocompatibility complex class II (MHCII) proteins. Here, Eagle et al. developed a transcription network decomposition...

You do not currently have access to this content.